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ABSTRACT 
Objective: The main aim of the study is to analyze the prescribing patterns and cost-effective analysis of single therapy and combination therapy 
oral anti-diabetic drugs, awareness of patients about diabetes, medication and lifestyle modification in the geriatrics population.  
Methods: A prospective study was carried out over a period of 12 mo in the region of Punganur Andhra Pradesh. Type 2 diabetic patients who were 
on oral anti-diabetic drugs were enrolled in the study. A suitable data collection form was prepared and used to collect the required data. The 
demographic data, disease data and the utilization of various oral anti-diabetic agents were analyzed. About 800 patients were enrolled for the 
study from rural and urban areas in Punganur. Among the study population, 63% (504) were males and 37% (296) were females in the age group of 
55 y and above. The majority of patients were from urban areas 70% (560) and 30% (240) were from rural areas. About 78 % of the patients have a 
history of diabetes more than 10 y and 22% were more than 5 y and less than 10 y.  
Results: The present study found that type 2diabetes was prevalent in males than females. Results show two anti-diabetic drugs of single drug and 
fixed dose combination per prescription was more than the single anti-diabetic drug also found new prescription was observed more and cost of 
treatment was immense when compared to old prescription. Prescription pattern exposed Glibenclamide, Metformin, Glipizide and Glimepiride 
were the most common drugs used among the various oral antidiabetics. Currently, newer drug DPPi 4 inhibitors like Sitagliptin, Vildagliptin and 
Teneligliptin are used as single and combination with metformin were increased in prescription. Among the various oral antidiabetics prescribed, 
the cost of 2 drugs per prescription and newer anti-diabetic drugs like DPPi4 was high but cost analysis study revealed the availability low cost 
brands in market. 
Conclusion: The study concluded that Prescription pattern and cost analysis of marketed anti-diabetic drug might be helpful for the professional to 
prescribe low cost effective medication. 
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INTRODUCTION 
India has one of the largest populations of diabetes in the world. The 
International Diabetes Federation (IDF) estimates the number of 
people with diabetes in India will reach 80 million by the year 2025. 
A survey depicts that 4% of adults in India suffered from diabetes in 
the year 2000 and is expected to increase to 6% by the year 2025. 
The World Health Organization (WHO) has projected that the global 
prevalence of type 2 diabetes mellitus will more than double from 5 
million in 1995 to 300 million by 2025. Between 1995 and 2025, 
there will be a 35% increase in the worldwide prevalence of 
diabetes mellitus, from 4 to 5.4% [1, 2].  
Diabetes mellitus (DM) is a group of metabolic disorders 
characterized by hyperglycemia; is associated with abnormalities in 
carbohydrate, fat and protein metabolism; and results in chronic 
complications including microvascular, macrovascular, and 
neuropathic disorders. When the amount of glucose in the blood 
increases, e. g., after a meal, it triggers the release of the hormone 
insulin from the pancreas [3, 4]. 
Blood glucose levels are mainly determined by absorption of glucose 
from gut, uptake of glucose by peripheral tissues, hepatic glucose 
output and insulin secretion from pancreas. Various oral anti-
diabetic agents act by modifying the factors aiding in the control of 
hyperglycemia. The treatment of diabetes can be done with 
conventional oral hypoglycemic agents [5, 6]. 
Environmental factors such as Lifestyle factor in type 2 diabetes 
provide evidence that overeating, especially when combined with 
obesity is associated with the development of type 2 diabetes. 
Obesity probably acts as a diabetogenic factor in those who are 
genetically disposed to develop type2 diabetes. Age factor is an 
important risk factor for type 2 diabetes. It is principally a disease of 
the middle-aged and elderly, affecting 10% of the population over 
the age of 65 [7, 8]. Patients over 75 y of age have a higher risk of 
developing multiple complications than the age group of 65-74. 
Older adults are at higher risk for developing type 2 diabetes 
because of the combined effects of increased insulin resistance and 
pancreatic islet dysfunction. 
MATERIALS AND METHODS 
Prescription pattern and cost analysis of anti-diabetic drugs 
This was a cross-sectional, prospective, observational study carried 
out in Home based review of prescription in rural and urban area of 
Punganur region in Andhra Pradesh, Spanadana Hospital Punganur. 
Permission from institutional ethical committee was obtained prior 
to the conduct of the study from Dr Sundaram, Authority of 
Spanadana Hospital (Institutional Ethical committee No: 
IEC/SPH/2016/02). The sample size for this study was 800 patients 
(100% confidence) in accordance with World Health Organization 
(WHO) manual to assess drug use in individual facilities [9]. It was a 
pilot study with duration of 12 mo in which 800 patients of diabetes 
of 55 y and above receiving antidiabetic therapy for more than 1 y 
was randomly selected for participation after fulfilling 
inclusion/exclusion criteria, Inclusion criteria are characteristics 
that the prospective subjects must included in the study were 
patients with>55 y of age, Study targeted the diabetic patient and 
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patients with Diabetics with minimum of 5years included in this 
study. Exclusion criteria are those characteristics that disqualify 
prospective subjects from inclusion in the study of Patients 
having<55 y of age excluded from the study, Diabetic with seriously 
ill (mortality condition) and reluctance, Study limited to persons 
with co morbid conditions. After obtaining informed consent, socio-
demographic data along with details of anti-diabetic drug therapy, 
duration of treatment and lifestyle modifications were recorded. In 
addition, cost of prescribed molecule of anti-diabetic versus trade 
name of drugs was analyzed from reliable source.  
Average number of anti-diabetic drugs per prescription, percentage 
of the different class of anti-diabetic drug prescribed, commonest 
class and type of anti-diabetic drugs prescribed, percentage of anti-
diabetic drugs prescribed from essential drug list from WHO and 
Indian National Essential Drug List [10, 11]. Patients were 
categorized with age, sex, rural and urban populated. The 
prescriptions were categorized as single and combination therapy. 
RESULTS 
Demographic data of diabetic patient 
Fig. 1 summarizes the demographic characteristics of the patient 
who involved in this study. The age of patients was 55-75 and above 
in which male 63% female 37% from 30% of rural population and 
70% of urban area. 
  
 
Fig. 1: Demographic Data of study population 
 
Prescription pattern of different classes of oral anti-diabetic 
drugs 
The different classes of oral anti-diabetic drug Sulfonylurea (SF), 
Biguanide (BG), Thiazolidinediones (TZ), Dipeptidyl peptidase-4 
inhibitor (DPP-4i), Fixed-dose combination (FDC) of Sulfonylurea 
plus Biguanide, Sulfonylurea plus Thiazolidinediones, and 
Sulfonylurea plus Dipeptidyl peptidase-4 inhibitor was noted in 
prescription. The percentage of prescription for the single drug in 
class sulfonylurea and biguanide was 36% and 20% it was 
comparatively more than the sulfonylurea like Glipizide (8.37%), 
Glimepride (12%) and Pioglitazone (1%). DPPi Sitagliptin and 
vildagliptin prescription was 1and3% of prescription and 
teneligliptin has 10% of total prescription.  
FDC of Glimepride, Glipizide, Pioglitazone, Sitagliptin, Vildagliptin, 
Teneligliptin with Metformin prescription was 24%, 16%, 5%, 2%, 
13% and 9% respectively. 
 
 
Fig. 2: Prescription pattern of Anti-diabetic drugs 
 
 
Fig. 3: Data showing the number of anti-diabetic drug per prescription 
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Oral Anti-diabetic drugs per prescription 
The fig. 3 shows three types of oral anti-diabetic medication per 
prescription such as single drug, two drugs and Single drug plus one 
fixed-dose combination (FDC) was 35.5%, 14% and 51% respectively. 
Co-morbidities of diabetic patient 
There are seven major disorders associated with diabetic patient 
revealed in fig. 4. Total of 112 (14%) patients among the study 
population had associated kidney Disorder, Hypertension in 456 
(14%) patients, hyperlipidemia, in 128 (16%), Vision Problem in 
312 (39%), a neurological disorder in 86 (11), Lung Disorder in 92 
(12%), the Liver disorder in 24 (3%) and Diabetic foot 32 (4%) was 
noted. In one Diabetic populated affected with two or more co-
morbidities. 
Comparative cost analysis of oral anti-diabetic drug versus 
trade name 
The following fig. 5-19 present the information of cost of different 
oral anti-diabetic drugs (OAD) available in different trade/brand 
names in India also in Andhra Pradesh. Cost of Different Brand of 
oral Anti-diabetic drugs treatment once a day for 360 d was 
calculated. The list of the drug in a different class of drug price was 
vary and in same classes of drug with brand name also were 
different some brand of same class was same also increased price 
was also listed. The following table shows the newer drugs like FDC 
teneligliptin, vildagliptin with metformin shows markedly more 
number of prescription since last two years, nowadays it will 
substituted by FDC of glimepride and glipizide at the same time cost 
of the treatment was high [12]. 
 
 
Fig. 4: Co-morbidities of diabetic patient 
 
 
Fig. 5: Comparative cost analysis of glibenclamide versus trade name 
 
 
Fig. 6: Comparative cost analysis of metformin 500 mg versus trade name 
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Fig. 7: Comparative cost analysis of glipizide 5 mg versus trade name 
 
 
Fig. 8: Comparative cost analysis of glimepride versus trade name 
 
 
Fig. 9: Comparative cost analysis of gliclazide versus trade name 
 
 
Fig. 10: Comparative cost analysis of pioglitazone versus trade name 
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Fig. 11: Comparative cost analysis of sitagliptin versus trade name 
 
 
Fig. 12: Comparative cost analysis of vildagliptin versus trade name 
 
 
Fig. 12: Comparative cost analysis of vildagliptin versus trade name 
 
 
Fig. 13: Comparative cost analysis of teneligliptin 20 mg versus trade name 
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Fig. 14: Comparative cost analysis of glimepride+metformin 2/500 mg versus trade name 
 
 
Fig. 15: Comparative cost analysis of glipizide+metformin 5/500 mg versus trade name 
 
 
Fig. 16: Comparative cost analysis of pioglitazone+metformin versus trade name 
 
 
Fig. 17: Comparative cost analysis of sitagliptin+metformin 50/500 mg versus trade name 
 
Gautam et al. 




Fig. 18: Comparative cost analysis of vildagliptin+metformin 50/500 mg versus trade name 
 
 
Fig. 19: Comparative cost analysis of teneligliptin+metformin 20/500 mg versus trade name 
 
DISCUSSION 
The incidence of DM increases with aging. As a result, adults may be 
diagnosed incidentally after the age of 65, or may have had a 
diabetes diagnosis in middle age or earlier onset. Having different 
demographic and clinical characteristics of these two groups may 
cause confusion caused by the setting of the general treatment 
recommendations. Age-related DM is characterized by lower A1C 
and the use of less insulin, with frequent occurrence in non-Hispanic 
whites. In comparison to adults with diabetes diagnosed in middle 
age, the retinopathy story is more prominent in late-onset diabetic 
cases, and interestingly there is no difference in the prevalence of 
cardiovascular disease (CVD) or peripheral neuropathy according to 
age at onset [13]. In diabetic adults increased development risk of 
lower extremity amputation, myocardial infarction (MI), impaired 
vision and end-stage renal disease. The present study result confirm 
the above statement of co-morbidities like diabetic nephropathy, 
Hypertension in diabetic patient  
There are distinct classes of hypoglycemic agents such as biguanides, 
sulfonylureas, thiazolidinediones, and DPP-4 inhibitors. Describe their 
mechanism of action, to allow physicians to individualize and better 
treatment of diabetic people. Also provide cost-effective and economic 
treatment when patient condition was cotrolled by FDC of 
metformin+Glimepride or Glipizide or Pioglitazone instead of FDC of 
Metformin+Sitagliptin/Vildagliptin/Teneligliptin whis was high price 
medication. 
Biguanides are old agents that work by reducing hepatic glucose 
output and, to a lesser extent, enhancing insulin sensitivity in 
hepatic and peripheral tissues. In contrast to sulfonylureas, 
metformin does not directly stimulate insulin secretion; its major 
effects are to increase insulin action and insulin-mediated glucose 
utilization in peripheral tissues (such as muscle and liver), 
particularly after meals, and to decrease hepatic glucose output. 
thiazolidinediones act mainly by improving peripheral uptake and 
utilization of glucose in muscle and fat, finally decreasing liver 
glucose production [14-16]. DPP-4 rapidly degrades and inactivates 
GLP-1, GIP, and other peptides in vivo via cleavage of N-terminal two 
amino acids. Inhibition of this enzyme leads to an increase in 
circulating endogenous GLP-1 and GIP levels. DPP-4 inhibitors 
mimic the therapeutic effects of incretin mimetics including 
stimulation of insulin secretion, inhibition of glucagon secretion, 
possibly preservation of b-cell mass and inhibition of apoptosis. 
These drugs display quite similar efficacy in lowering HbA1C (_1% 
reduction) compared with other antihyperglycemic agents, but they 
are weight neutral and have a low potential for hypoglycaemia when 
used as monotherapy [17, 18]. 
Glucose intolerance increases progressively by aging and the 
characteristic feature of diabetes in elderly patients is especially 
postprandial hyperglycemia. Decrease in beta-cell-compensating 
capacity with advancing age, leads to insulin resistance and it 
appears as postprandial hyperglycaemia in the elderly [19]. 
Therefore, the prevalence varies according to the tests used during 
diagnosis on elderly patients. One-third of the individuals who are 
tested with A1C or fasting plasma glucose (FPG) are cannot get a 
diagnosis [20]. 
The burden of treatment of older diabetic patients on the country 
economy is quite high. According to the analysis made in the in 2010 
More than 14 million patients whose age 65 and over are hospitalized 
annually and approximately one-third of them are diabetic [21]. Again 
according to data, about 245 million is spent yearly on diabetes 
patients, of which 176 million is direct medical costs, while 69 million 
is the loss of production and mortality [22]. In addition, 59% portion 
of the annual treatment costs has been made for elderly diabetic 
individuals. Most of the expenditures are caused by hospital 
admissions, home care and prescribed drugs, the extreme 
expenditures per person, depending on gender and age [23].  
The present study shows that type 2 diabetes was more prevalent in 
males than females. The elderly patients were at high risk of 
developing type 2diabetes. A total of 800 patients had co-morbid 
conditions along with diabetes and commonly seen co-morbid 
conditions in the study were hypertension, impaired vision and 
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renal disorder. The study has shown sulfonylurea and biguanide 
mainly metformin as the predominantly prescribed oral antidiabetic 
drug both in monotherapy and in combination therapy. Overall, 
monotherapy was found to be predominant over combination 
therapy. There was a significant increase in the prescriptions of 
newer oral antidiabetic agents like DPP-4 inhibitors. It may be 
concluded that the incidence of polypharmacy is increased when 
compared to olden days and the essential drug prescription is high 
and therefore drug use is quite rational. The present study also 
found that a number of new prescription combinations like 
metformin with sitagliptin, Vildagliptin and teneligliptin. Improving 
patient knowledge on correct medication will perhaps boost up the 
health care setting not only in hospital and outpatient setting also. 
The prescription pattern and cost analysis result shows single and 
fixed drug combination of prescription in diabetic geriatric patient. 
In starting day’s single drug was used effectively for controlling of 
blood sugar level but now a day dual therapy along with single-drug 
therapy prescription was increased and also old drugs replaced by 
newer drug for effectively maintain the homeostatic condition of 
blood glucose level, at same time cost of the newer drug was high. It 
may influence the economical status of patient so effective 
prescription pattern may needed to improve cost-effective and 
economical status of geriatric. Comparatively high-cost availability 
of different brands were more but still low cost brand medication 
was also available it may helpful to reduce the economic burden of 
geriatric patient, mostly in patient with co-morbidity and also avoid 
potentially inappropriate medication in prescription. 
CONCLUSION 
Thus this study strongly highlights the cost analysis of different 
classes of diabetic drug with different available brand in market so 
that we can improve the patient’s economical condition. Out of 800 
patients no of patient from urban area was more when compared to 
rural area. It might be due to the life style modification in urban 
area. So educate the people for life style modification at the same 
time rural area the co-morbidity condition of diabetic foot was high. 
So it is must and important to educate the patient to protect foot 
away from injury and infections. 
The current study concluded that due to current lifestyle 
modifications with single therapy alone cannot achieve a good 
glycemic control, a second drug selected among the sulfonylureas, 
thiazolinediones and DPPi 4 drugs must be used. To avoid 
therapeutic inertia, thus therapy should be modified into newer 
drugs like teneligliptin, metformin with DPPi 4 combination drugs 
shows in more prescriptions in the last few years to keep glycemic 
control. In this second step, various factors such risk of 
hypoglycemia, comorbidities, age of patients and presence of 
diabetic complications and cost of treatment must be properly 
considered to individualize treatment. 
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